Literature DB >> 21324459

Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans.

Anetta Undas1, Tomasz Nowakowski, Mariola Cieśla-Dul, Jerzy Sadowski.   

Abstract

BACKGROUND: A role of blood coagulation in the pathogenesis of peripheral arterial disease (PAD) and Buerger's disease, or thromboangiitis obliterans (TAO), remains unclear.
OBJECTIVE: To test the hypothesis that PAD and TAO are associated with prothrombotic phenotype of a fibrin clot. PATIENTS AND METHODS: Ex vivo plasma fibrin clot permeability, turbidimetry and efficiency of fibrinolysis were investigated in 106 patients with PAD and 20 patients with TAO and compared with the respective control groups matched for age, sex, and cardiovascular risk factors. The progression of PAD and TAO were evaluated during follow-up of 3-7.5 years. PAD patients were characterized by lower clot permeability (-18.8%, p=0.005), shorter lag phase (-35.3%, p<0.001), higher maximum clot absorbancy (+22.4%, p<0.001), prolonged clot lysis time (+30.6%, p=0.003), and lower rate of D-dimer release from clots in the presence of recombinant tissue plasminogen activator (-16.5%, p=0.009), but twofold lower maximum D-dimer levels released from clots during lysis (p<0.001) than the controls. Similar, but more pronounced abnormalities were observed in TAO patients versus controls (all p<0.01). Seventeen PAD (16%) and 3 (15%) TAO patients were lost to follow-up. The progression observed in 47 (52.8%) PAD patients and 10 (59%) TAO patients was associated with lower clot permeability (-14.6%, p=0.009, and -17.5%, p=0.02) and prolonged clot lysis (+11.3%, p=0.004, and +12.4%, p=0.03, respectively).
CONCLUSIONS: Unfavorably altered fibrin clot properties are observed in both PAD and TAO. Denser fibrin clots with reduced susceptibility to lysis might characterize the progression of both diseases during long-term follow-up.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21324459     DOI: 10.1016/j.atherosclerosis.2010.12.040

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate.

Authors:  Xueming Wu; Niranjan Balu; Wen Li; Yong Chen; Xiaoyue Shi; China M Kummitha; Xin Yu; Chun Yuan; Zheng-Rong Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-09-19

2.  The prolonged clotting time in two female patients with thromboangiitis obliterans.

Authors:  Yiping Dang; Yin Xia; Yiqing Li; DannyC W Yu
Journal:  BMJ Case Rep       Date:  2013-06-06

3.  Clot strength is negatively associated with ambulatory function in patients with peripheral artery disease and intermittent claudication.

Authors:  Karin Mauer; Andrew W Gardner; Tarun W Dasari; Julie A Stoner; Steve M Blevins; Polly S Montgomery; Jorge F Saucedo; J Emilio Exaire
Journal:  Angiology       Date:  2014-04-27       Impact factor: 3.619

4.  Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.

Authors:  Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  Transl Res       Date:  2019-08-29       Impact factor: 7.012

5.  Increased Clot Formation in the Absence of Increased Thrombin Generation in Patients with Peripheral Arterial Disease: A Case-Control Study.

Authors:  Marie-Claire F Kleinegris; Joke Konings; Jan W Daemen; Yvonne Henskens; Bas de Laat; Henri M H Spronk; Arina J Ten Cate-Hoek; Hugo Ten Cate
Journal:  Front Cardiovasc Med       Date:  2017-04-20

Review 6.  To What Extent Are the Terminal Stages of Sepsis, Septic Shock, Systemic Inflammatory Response Syndrome, and Multiple Organ Dysfunction Syndrome Actually Driven by a Prion/Amyloid Form of Fibrin?

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Semin Thromb Hemost       Date:  2017-08-04       Impact factor: 4.180

Review 7.  Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.

Authors:  Vassilios P Memtsas; Deepa R J Arachchillage; Diana A Gorog
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

8.  Polyphosphate delays fibrin polymerisation and alters the mechanical properties of the fibrin network.

Authors:  Claire S Whyte; Irina N Chernysh; Marco M Domingues; Simon Connell; John W Weisel; Robert A S Ariens; Nicola J Mutch
Journal:  Thromb Haemost       Date:  2016-08-25       Impact factor: 5.249

9.  Cilostazol on the expression of ICAM-1, VCAM-1 and inflammatory factors in plasma in patients with thromboangiitis obliterans.

Authors:  Fuchen Song; Bo Ji; Ting Chen
Journal:  Exp Ther Med       Date:  2018-07-11       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.